Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants
Abstract
Background: In Japan, migraine is estimated to affect 6-8.6% of the population, and the burden of migraine and barriers to migraine care are substantial. Although new preventive treatments are available for migraine, there is limited qualitative information about the lived experience of adults with migraine in Japan and how these treatments improve their day-to-day lives.
Methods: Participants in a qualitative interview study embedded in a phase 3 randomized, double-blind, placebo-controlled clinical trial (NCT03812224) were invited to take part in a telephone interview after completing 24 weeks of double-blind treatment with once-monthly erenumab 70 mg and a subsequent 28-week open-label treatment period. Interviews were conducted by Japanese interviewers using a semi-structured interview guide. The interviews were audio-recorded, transcribed, and qualitatively analysed using a thematic content analysis approach.
Results: Forty-one participants were interviewed between May and September 2020. The mean age of participants was 43.8 years; 82.9% were female, 51.2% had episodic migraine, and 48.8% had chronic migraine. Prior to trial participation, patients identified pain, nausea, and profound tiredness-often expressed as a "lack of energy" or feeling "exhausted" or "drained"-as the most bothersome symptoms. Patients also emphasized difficulties concentrating, interference with school, work, and household responsibilities, and emotional strain as the most bothersome impacts of…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.